In8bio Company Insiders
| INAB Stock | USD 2.17 0.03 1.36% |
In8bio employs about 18 people. The company is managed by 10 executives with a total tenure of roughly 42 years, averaging almost 4.0 years of service per executive, having 1.8 employees per reported executive. Analysis of In8bio's management performance can provide insight into the company performance.
In8bio Management Team Effectiveness
The company has return on total asset (ROA) of (0.7325) % which means that it has lost $0.7325 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7467) %, meaning that it created substantial loss on money invested by shareholders. In8bio's management efficiency ratios could be used to measure how well In8bio manages its routine affairs as well as how well it operates its assets and liabilities.In8bio Workforce Comparison
In8bio Inc is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 439. In8bio holds roughly 18.0 in number of employees claiming about 4% of equities under Health Care industry.
In8bio Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific In8bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on In8bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, In8bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Greenwood Luba over three weeks ago Acquisition by Greenwood Luba of 63150 shares of In8bio at 0.17 subject to Rule 16b-3 | ||
Roemer Alan S. over a month ago Disposition of 102459 shares by Roemer Alan S. of In8bio at 0.1844 subject to Rule 16b-3 | ||
Greenwood Luba over a month ago Acquisition by Greenwood Luba of 63150 shares of In8bio at 0.17 subject to Rule 16b-3 | ||
Mccall Patrick over two months ago Disposition of 20492 shares by Mccall Patrick of In8bio at 1.5 subject to Rule 16b-3 | ||
Kreis Leslie W. over two months ago Disposition of 574241 shares by Kreis Leslie W. of In8bio at 1.5 subject to Rule 16b-3 | ||
William Ho over two months ago Disposition of 81967 shares by William Ho of In8bio at 0.45 subject to Rule 16b-3 | ||
Brandt Peter C. over two months ago Disposition of 81967 shares by Brandt Peter C. of In8bio at 0.1844 subject to Rule 16b-3 | ||
Brandt Peter C. over two months ago Disposition of 81967 shares by Brandt Peter C. of In8bio at 1.5 subject to Rule 16b-3 |
In8bio Notable Stakeholders
An In8bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as In8bio often face trade-offs trying to please all of them. In8bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting In8bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Patrick CPA | CFO Secretary | Profile | |
| Pharm MPH | VP Communications | Profile | |
| TaiWei Ho | President, CoFounder | Profile | |
| William Ho | President, CoFounder | Profile | |
| Trishna MD | Chief Officer | Profile | |
| Kate Rochlin | Chief Officer | Profile | |
| Lawrence Lamb | CoFounder VP | Profile | |
| Kenneth LaMontagne | Sr Devel | Profile | |
| Michael McNamara | Vice Accounting | Profile | |
| Melissa Beelen | Vice Operations | Profile |
About In8bio Management Performance
The success or failure of an entity such as In8bio Inc often depends on how effective the management is. In8bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of In8bio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the In8bio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York. In8Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people.
Please note, the presentation of In8bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, In8bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of In8bio's management manipulating its earnings.
In8bio Workforce Analysis
Traditionally, organizations such as In8bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare In8bio within its industry.In8bio Manpower Efficiency
Return on In8bio Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.7M | |
| Net Loss Per Executive | 3M | |
| Working Capital Per Employee | 527.5K | |
| Working Capital Per Executive | 949.5K |
Complementary Tools for In8bio Stock analysis
When running In8bio's price analysis, check to measure In8bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy In8bio is operating at the current time. Most of In8bio's value examination focuses on studying past and present price action to predict the probability of In8bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move In8bio's price. Additionally, you may evaluate how the addition of In8bio to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |